W. Stewart Campbell

Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022

Retrieved on: 
Tuesday, November 1, 2022
Autism, GLOBE, Axial, Bacteria, W. Stewart Campbell, Learning, Therapy, Irritability, Drug development, Central nervous system, Pharmaceutical industry

The event will bring together 300+ leaders from the microbiome community for three days of learning, networking and forging successful partnerships at a pivotal time for microbial drug development.

Key Points: 
  • The event will bring together 300+ leaders from the microbiome community for three days of learning, networking and forging successful partnerships at a pivotal time for microbial drug development.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
  • The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
  • Axials lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.

Axial Therapeutics to Present at BioJapan Conference

Retrieved on: 
Thursday, October 6, 2022
Drug discovery, Therapy, University of Tokyo, Lists of diseases, W. Stewart Campbell, University, Irritability, Autism, Bacteria, GLOBE, Axial, Central nervous system, Fine chemical, Pharmaceutical industry

To learn more about BioJapan, visit https://jcd-expo.jp/en/ .

Key Points: 
  • To learn more about BioJapan, visit https://jcd-expo.jp/en/ .
  • Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
  • The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
  • The company is advancing a pipeline of microbial-inspired therapeutics for conditions with significant unmet patient need, including autism and Parkinsons disease, and is also pursuing pre-clinical discovery of gut-targeted therapies in oncology.

Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference

Retrieved on: 
Tuesday, September 13, 2022
Therapy, Central nervous system, Lists of diseases, W. Stewart Campbell, Organic, Targeted therapy, Patient, Irritability, Chief executive officer, Bacteria, Axial, GLOBE, Autism, Pharmaceutical industry

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled The Next Wave of Targeted Therapies at the Longwood Healthcare Leaders Fall webconference on Wednesday, September 21, 2022.

Key Points: 
  • WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled The Next Wave of Targeted Therapies at the Longwood Healthcare Leaders Fall webconference on Wednesday, September 21, 2022.
  • Longwood Healthcare Leaders meetings bring together leading biotech and pharma CEOs, heads of R&D, top academics, and healthcare investors for off-the-record discussions to drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients.
  • The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
  • Axials lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.

Axial Therapeutics Announces Participation of its CEO, A. Stewart Campbell, in Longwood Healthcare Leaders Spring MIT Webconference

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Organic, Lists of diseases, Autism, W. Stewart Campbell, Patient, Therapy, Irritability, Axial, Bacteria, Chief executive officer, Central nervous system, Pharmaceutical industry

Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled Placing Patients At The Center at the Longwood Healthcare Leaders Spring MIT webconference on Wednesday, May 4, 2022.

Key Points: 
  • Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled Placing Patients At The Center at the Longwood Healthcare Leaders Spring MIT webconference on Wednesday, May 4, 2022.
  • Longwood Healthcare Leaders meetings bring together leading biotech and pharma CEOs, heads of R&D, top academics, and healthcare investors for off-the-record discussions to drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
  • The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.